Adopting the Evolving Management of HR+/HER2-mBC into Practice copertina

Adopting the Evolving Management of HR+/HER2-mBC into Practice

Adopting the Evolving Management of HR+/HER2-mBC into Practice

Di: Annenberg Center for Health Sciences
Ascolta gratuitamente

A proposito di questo titolo

Survival outcomes for patients with HR+/HER2- mBC remain suboptimal, despite first-line treatment strategies with endocrine therapy (ET). Greater understanding of the biology of HR+/HER2- mBC, including the role of biomarkers like ESR1 mutations, and the development of biopsy techniques for early mutation detection, have paved the way for personalized treatment approaches. In this activity, medical oncologists discuss integrating these evidence-based advancements into practice.Annenberg Center for Health Sciences Disturbo fisico e malattia Igiene e vita sana
  • Therapeutic Approaches for the Treatment of Patients with HR+/HER2- mBC
    Apr 9 2025

    Therapeutic Approaches for the Treatment of Patients with HR+/HER2- mBC

    Mostra di più Mostra meno
    21 min
  • Navigating Through the Current Treatment of Patients with HR+/HER2- mBC
    Apr 9 2025

    Navigating Through the Current Treatment of Patients with HR+/HER2- mBC

    Mostra di più Mostra meno
    7 min
  • Molecular and Tumor Profiling
    Apr 9 2025

    Molecular and Tumor Profiling

    Mostra di più Mostra meno
    23 min
Ancora nessuna recensione